SCHEMBL21687763

SCHEMBL21687763

N#Cc1cc(-c2c(C#N)cccc2[Si](c2ccccc2)(c2ccccc2)c2ccccc2)ccc1-n1c2ccccc2c2ccccc21

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.35
ALDH1A1 P00352 4/20 0.35
TDP1 Q9NUW8 3/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
TSHR P16473 2/20 0.35
MAPT P10636 2/20 0.34
STAT3 P40763 1/20 0.34
HIF1A Q16665 1/20 0.34
HTT P42858 2/20 0.33
IMPDH2 P12268 1/20 0.33
KDM4E B2RXH2 1/20 0.33
HSD17B10 Q99714 1/20 0.33
NPSR1 Q6W5P4 1/20 0.32
AR P10275 1/20 0.32
CNR2 P34972 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21688067 0.94 PTGER4 (0.33) SMN1; SMN2ALDH1A1TDP1MEN1KMT2A
SCHEMBL21687767 0.92 SMN1; SMN2 (0.34) SMN1; SMN2ALDH1A1TDP1MEN1KMT2A
SCHEMBL21687726 0.87 SMN1; SMN2 (0.36) SMN1; SMN2ALDH1A1TDP1HIF1AIMPDH2
SCHEMBL21688265 0.86 SMN1; SMN2 (0.33) SMN1; SMN2ALDH1A1TDP1HIF1AHTT
SCHEMBL21688070 0.86 PTGER4 (0.33) SMN1; SMN2ALDH1A1TDP1MEN1KMT2A
SCHEMBL21687973 0.86 KDM4E (0.39) SMN1; SMN2ALDH1A1TDP1MEN1KMT2A
SCHEMBL21687609 0.86 ALDH1A1 (0.34) SMN1; SMN2ALDH1A1TDP1MEN1KMT2A
SCHEMBL21688077 0.86 KDM4E (0.41) SMN1; SMN2ALDH1A1TDP1MEN1KMT2A
SCHEMBL21688042 0.85 ALDH1A1 (0.34) SMN1; SMN2ALDH1A1TDP1MEN1KMT2A
SCHEMBL21687786 0.85 SMN1; SMN2 (0.36) SMN1; SMN2ALDH1A1TDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11201300-B2 Condensed cyclic compound and organic light-emitting device including condensed cyclic compound SAMSUNG ELECTRONICS CO., LTD. (KR) 2021-12-14 US disclosed
US-20200044168-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND SAMSUNG ELECTRONICS CO., LTD. (KR) 2020-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200044168-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND CRY1, CCNL2, CCNE2 SMN1; SMN2 4039/4885ALDH1A1 616/4885TDP1 3040/4885
US-11201300-B2 Condensed cyclic compound and organic light-emitting device including condensed cyclic compound CRY1, CCNL2, CCNE2 SMN1; SMN2 4039/4885ALDH1A1 616/4885TDP1 3040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.